Pediatric Formulation Development A quality perspective Julia C.
Pediatric Formulation Development A quality perspective Julia C. Pinto, Ph.D. Branch Chief, Office of New Drug Products Office of Product Quality, CDER, FDA Chemistry, Manufacturing and Controls (CMC) perspective Extemporaneous preparations using approved adult drug product for pediatric use Compounding of approved adult drug product for pediatric use Design and manufacture of drug product for Pediatric patients. www.fda.gov 2
Limitations in Developing Extemporaneous Formulations Lack of stability/sterility studies Excipients used for the approved adult formulation Dosing, Efficacy and safety concerns
Variations in practice www.fda.gov 3 Limitations in compounding of a drug substance for pediatric administration Selection of Excipients Stability of the compounded product Sterility of the compounded product Content and Blend uniformity Viscosity (dosing limitations) Dissolution www.fda.gov
4 CMC Requirements for IND submissions using Compounding or Extemporaneous Formulations Quantitative Composition (Excipient safety) and method of preparation Certificate of analysis comprising: Assay determination; Impurity profile (degradation); Content or blend uniformity; microbial or sterility data (if applicable) Stability data www.fda.gov 5
Challenges in New Formulation Development Dose flexibility: accuracy of dosing low doses and small volumes across all the age groups (infants to tweens) Route of administration and bioequivalence: Inability to swallow tablets/capsules Patient Compliance: palatability, smell, texture Choice of Excipients and Toxicity Physical and Chemical Properties of the Drug Substance Solubility, pka, stability in liquids and foods www.fda.gov 6 Dosage Form Variability Per Pediatric Age Groups Age
Common Dosage Forms Neonates: 0-4 weeks Indication dependent Infants: 1 mth 2 years Liquids-small volumes (e.g., syrups, solutions) Children: 2 5 years Liquids; effervescent tablets dispersed in liquids; sprinkles on foods Solids (chewable tablets, orally disintegrating tablets;
oral films) Solids (typical adult dosage forms - tablets, capsules) Children: 6 11 years Adolescents: 12 - 18 years www.fda.gov 7 Challenges with Oral Solid Dosage Forms Manufacturing Content uniformity with very low doses Milling/Grinding Particle Size Tablet size and shape/capsule size
Scored tablets Controls Disintegration/dissolution Impurities/degradation products www.fda.gov 8 Challenges with Liquid Formulations Palatability (taste, texture, smell) Chemical Stability of Ready to Use Solutions or Suspension Physical Stability of Suspensions Proper Measuring Device(s) Suitable Container/Closures (leachable/extractables)
Excipients (safety consideration) www.fda.gov 9 Excipient Toxicity in Young Children Excipient Administration Adverse reaction Benzyl alcohol Oral, parenteral
Precipitation Discoloration Degradation Loss of potency Microbial Endotoxin testing/Sterility/ Particulate matter caking - difficulty in dispersing the powder upon reconstitution loss of potency chewable tablet hardening friability 11 Example #1: Prilosec Modified/increased labeling to include 1 16 year olds Delayed-Release Oral Suspension
Supplied as 2.5 or 10 mg unit dose packets Directions: Empty contents of packet into 5 or 15 mL of water, let sit 2 minutes, drink Contents of capsules may also be sprinkled on apple sauce 12 Example #2: Zenpep and Creon (pancrealipase) New 3,000 USP units of lipase capsule Indicated for infants 12 months Contents of capsule may be sprinkled on soft acidic food such as apple sauce Contents should not be mixed directly into formula or breast milk 13
Conclusions: Pediatric Product Design and Manufacture Critical CMC Controls (compounding/extemporaneous preparations) API stability (maintain potency) Degradation (impurity profile) Blend Uniformity Dissolution (solid dosage forms) Microbial/sterility testing New Product Profile Dose Flexibility (specific pediatric age group(s)) Palatable Stable long term Maintain Bioequivalence to Adult Formulation 14
Recall Radians Sinusoidal Source Example 1, 2, 3 Complete RL Response Complex Numbers & Phasors Example 4 Bibliography Why AC? Except for batteries, most electric devices rely on AC, and not on DC. Why AC?
Florida's Progress Monitoring and Reporting Network (the PMRN) gives schools a way of recording their . reading. data that generates reports which meet these guidelines. You can see that the data allow for comparisons of progress in specific skills (such...
What are the principle components of telecommunications networks and key networking technologies? KEY DIGITAL NETWORKING TECHNOLOGIES + The Development of widely used comm. standards * TCP/IP: Transmission Control Protocol / Internet Protocol. A protocol is a set of rules and...
(TC) How does it work? A TC is a junction of two dissimilar metals. ... For others, please consult reference material.Here are the colors used in the USA (sleeve shows connector and jacket color): School of Biological, Chemical, and Environmental...
Bacchus, one of Caravaggio's baroque paintings, depicts the youthful Roman god of wine. This painting resides in Florence at the Uffizi Gallery.The inedible fruit in the painting is thought to depict the idea that time moves quickly and life is...
Meiosis in a nutshell. Meiosis goes through the steps of Mitosis twice with a little difference. the difference in the first set of divisions is that the DNA is crossed and mixed up to make more different babies. The second...
Axelrod: Simulation der Evolution Gefangenendilemma Gewinner: Anatol Rapoport's „Wie-du-mir-so-ich-dir-Strategie": Beginn mit einem ersten Zug der Zusammenarbeit Dann immer nur Kopie des letzten Zugs der Gegenüber Strategietypen Nette (niemals als erster verweigern) Gemeine (verweigern ohne provoziert zu sein) Verzeihend (verzichtet auf...